美国马里兰州罗克维尔市和中国香港，2018年2月21日–亚盛医药，一家全球临床阶段的生物医药公司，将出席2月21日至24日在美国加州圣塔莫妮卡市举行的国际肺癌研究协会（IASLC）第18届肺癌靶向治疗大会。
亚盛医药董事长杨大俊博士将在会上介绍公司在研的一项Bcl-2/Bcl-xL双重抑制剂APG-1252及其目前处于进展中的临床I期试验的初步数据。
ROCKVILLE, MD and HONG KONG, CHINA—February 21, 2018—Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate APG-1252, a novel Bcl-2/Bcl-xL dual inhibitor. The data will be presented by Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer, during the International Association for the Study of Lung Cancer (IASLC) 18th Lung Cancer Targeted Therapies Meeting, held in Santa Monica, CA from February 21-24.
关于APG-1252
APG-1252是一项在研的强效Bcl-2家族蛋白抑制剂小分子新药，其通过选择性抑制Bcl-2与Bcl-xL蛋白从而诱导癌症细胞程序性死亡即细胞凋亡。Bcl-2蛋白是公认的大多数血液肿瘤的主导致癌基因，而Bcl-xL蛋白是针对实体肿瘤治疗的一个新兴靶点。因Bcl-xL蛋白在成熟的血小板中表达，从而使Bcl-xL靶向药物面临血小板减少这一在靶毒副作用难题。基于合理化药物设计策略，APG-1252对血小板毒性远低于其它同类药物，同时在小细胞肺癌等实体瘤中表现出强效的抗肿瘤活性。APG-1252现处于临床I期阶段，用于治疗小细胞肺癌或其它实体瘤患者。
关于亚盛医药
亚盛医药是一家全球领先的处于临床阶段的新药研发企业，致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台及100多项国际发明专利。
公司研发产品管线主要专注细胞凋亡路径关键蛋白的抑制剂，通过抑制Bcl-2、IAP或MDM2-p53等，重启肿瘤细胞的凋亡程序；第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂；与肿瘤治疗有密切相关性的表观遗传学靶点的抑制剂等。公司现有六个新药项目已进入到中国、美国及澳大利亚的I-II期临床开发阶段，其中包括APG-1252，一个新型、强效的Bcl-2/BCL-xL双重抑制剂。更多相关信息请浏览公司官方网站www.ascentagepharma.com
媒体联络
AmyBonanno
电邮: abonanno@bmccommunications.com
电话: +1 914 450 0349
投资人联络
ChadRubin
电邮: crubin@troutgroup.com
电话: +1 646 378 2947
About APG-1252
APG-1252 is a highly potent investigational small molecule that selectively binds to and inhibits Bcl-2 and Bcl-xL proteins, both of which play pivotal roles in regulating programmed cell death, or apoptosis. APG-1252 is designed to overcome on-target toxicity of platelets that may occur during Bcl-xL inhibition, while maintaining strong anti-tumor potency. In preclinical studies, APG-1252 achieved complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose schedule, including small cell lung cancer (SCLC), coloncancer, breast cancer and acute lymphoblastic leukemia. APG-1252 also demonstrated strong synergy with chemotherapeutic agents, indicating that it may have broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is being investigated in Phase 1 clinical studies in patients with SCLC or other solidtumors.
About Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies forcancers, hepatitis B and aging-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For moreinformation, please visit www.ascentagepharma.com.
Media Contact
Amy Bonanno
E-mail: abonanno@bmccommunications.com
Phone: +1 914 450 0349
Investor Contact
Chad Rubin
E-mail: crubin@troutgroup.com
Phone: +1 646 378 2947
长按关注，亚盛医药最新动态尽在掌握！
